Compare ICCM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | ACET |
|---|---|---|
| Founded | 2006 | 1947 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 69.6M |
| IPO Year | 2013 | 2017 |
| Metric | ICCM | ACET |
|---|---|---|
| Price | $0.61 | $6.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $65.33 |
| AVG Volume (30 Days) | 169.8K | ★ 174.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.45 |
| 52 Week High | $1.53 | $9.05 |
| Indicator | ICCM | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 45.51 |
| Support Level | $0.59 | $6.41 |
| Resistance Level | $0.74 | $8.46 |
| Average True Range (ATR) | 0.03 | 0.52 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 73.86 | 29.06 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.